Ataraxis AI develops AI-powered precision medicine tools for cancer care, integrating digital pathology and clinical data to personalize treatment selection.
Ataraxis AI is a precision oncology company building AI-powered clinical tests to personalize cancer care. Its flagship platform, Ataraxis Breast, integrates routine digital pathology with clinical data to generate prognostic and predictive patient-specific insights.
The company was founded by Jan Witowski, MD, PhD, and Krzysztof Geras, PhD, and has developed AI foundation models such as Kestrel and Falcon trained on pan-cancer pathology data. Ataraxis Breast offers a suite of tests including RISK (recurrence prediction), CTX (chemotherapy benefit), and NEO (neoadjuvant therapy response), all delivered through a CLIA-certified laboratory with same-day turnaround.
AI-powered clinical tests for breast cancer treatment selection, integrating pathology and clinical data to predict recurrence risk and therapy response.
